- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02959411
Tolvaptan for Advanced or Refractory Heart Failure
Tolvaptan for the Management of Acute Decompensated Heart Failure in Patients With Advanced or Refractory Heart Failure
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Despite its demonstrated efficacy and tolerability, Tolvaptan remains underutilized for the treatment of acute decompensated heart failure (ADHF) in many centers. Post-hoc analysis suggests that Tolvaptan may provide optimal outcomes in patients with more advanced heart failure (HF) including those with cardiorenal syndrome, marked hyponatremia and severe congestion, or a combination of those conditions. The efficacy of Tolvaptan in HF patients with loop diuretic resistance and in those requiring inotropic support remains uncertain.
The purpose of this study is to examine the benefit of Tolvaptan versus the current standard of care diuretic therapy for patients hospitalized with ADHF and evidence of advanced or complex HF with severe hyponatremia. Patients with advanced or complex disease are defined as those with suboptimal diuretic response over a 48 hour period.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4Z6
- University of Calgary
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hospital admission for ADHF with volume overload as evidenced by ≥ 2 of the following: Elevated JVP, peripheral edema, ascites, pulmonary rales, congestion on chest X-ray, elevated NT-pro-BNP > 2000 pg/ml
- Inadequate clinical response indicated by body weight loss < 1.0 kg/day over 48 hours despite adequate doses of IV loop diuretic (at least 40 mg furosemide daily) and fluid restriction 2 L/24 hours.
- ≥1 of the following over the preceding 48 hours: Potential need for inotropic support to improve urine output, and/or renal insufficiency (estimated glomerular filtration rate <45 mL/min/1.73 m2)
- Serum sodium ≤134 mmol/L
- ≥18 years-old
Exclusion Criteria:
- Cardiac surgery within 60 days of enrollment
- Planned cardiac mechanical support or transplant; subjects with previously implanted ventricular assist device (VAD) will not be excluded
- Need for intravenous pressor support for symptomatic hypotension
- Biventricular pacemaker placement within the last 60 days
- Hemofiltration or dialysis
- Known cirrhosis
- Supine systolic arterial blood pressure less than 85 mmHg
- Refusal or inability to sign informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tolvaptan
Tolvaptan 15-60 mg, once daily for 4 days or until hospital discharge
|
Tolvaptan is a selective vasopressin receptor antagonist that inhibits activation of the V2 receptor and synthesis and insertion of the aquaporin2 channel into the apical membrane of the renal collecting duct.
Tolvaptan inhibits the reabsorption of free water, inducing free water diuresis and increasing serum sodium levels without adversely influencing electrolyte levels or stimulating the sympathetic nervous system or renin-angiotensin system.
Other Names:
|
Active Comparator: Standard of care diuretic therapy
Usual standard of care diuretic therapy for patients with acute decompensated heart failure
|
Usual standard of care diuretic therapy for patients hospitalized with acute decompensated heart failure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in body weight
Time Frame: From randomization to 96 hours after randomization
|
From randomization to 96 hours after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total 96 hour urine output
Time Frame: From randomization to 96 hours post randomization
|
Measured in ml urine
|
From randomization to 96 hours post randomization
|
Subjective change in shortness of breath
Time Frame: 48 hours after randomization and 96 hours post randomization
|
As assessed by a 5 point Likert scale
|
48 hours after randomization and 96 hours post randomization
|
Change in renal function
Time Frame: From randomization to 7 days post randomization
|
Measured by estimated glomerular filtration rate
|
From randomization to 7 days post randomization
|
Proportion of patients developing worsening renal function (WRF)
Time Frame: From randomization to 7 days post randomization
|
Categorical measure- need for renal replacement therapy or ultrafiltration or increase in serum creatinine by > 26 umol/L
|
From randomization to 7 days post randomization
|
Change in serum sodium
Time Frame: From randomization to 7 days post randomization
|
Measured in mmol/L
|
From randomization to 7 days post randomization
|
Length of hospitalization
Time Frame: From hospital admission to 30 days post randomization
|
Number of days in hospital
|
From hospital admission to 30 days post randomization
|
Need for intensive care unit admission
Time Frame: From hospital admission to 30 days post randomization
|
Categorical measure (yes/no)
|
From hospital admission to 30 days post randomization
|
Need for positive inotropic agent use
Time Frame: From randomization to 7 days post randomization
|
Categorical measure (yes/no)
|
From randomization to 7 days post randomization
|
Composite of Worsening Renal Function or need for inotropic agent
Time Frame: From randomization to 7 days post randomization
|
Worsening Renal Function defined as increase from serum creatinine at randomization of more than 30 umol/L at any time from randomization to 7 days.
This is a categorical outcome (yes/no)
|
From randomization to 7 days post randomization
|
30 day cardiovascular death and/or hospitalization
Time Frame: From Randomization to 30 days post randomization
|
Categorical outcome (yes/no)
|
From Randomization to 30 days post randomization
|
Clinical markers of congestion
Time Frame: From randomization to 96 hours after randomization
|
Described as total number of the presence of Jugular venous pressure (JVP) level, edema, rales, orthopnea, 3rd heart sound
|
From randomization to 96 hours after randomization
|
Change in N-terminal brain natriuretic peptide (NT-pro BNP)
Time Frame: From randomization to 96 hours post randomization compared to baseline
|
Measurement calculated in absolute value of NT-pro-BNP
|
From randomization to 96 hours post randomization compared to baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jonathan Howlett, MD, University of Calgary
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REB16-0064
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
Clinical Trials on Tolvaptan
-
Otsuka Pharmaceutical Development & Commercialization...RecruitingAutosomal Recessive Polycystic Kidney (ARPKD)United States, United Kingdom, Belgium, Poland, France, Germany, Italy
-
Regional Hospital HolstebroAarhus University HospitalCompleted
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
NYU Langone HealthWithdrawnSIADH | Cerebral Hyponatremia | Cerebral Salt-wasting Syndrome | Reset Hypothalamic OsmostatUnited States
-
Eli Lilly and CompanyActive, not recruitingPlaque Psoriasis | Psoriatic ArthritisIndia
-
Otsuka Pharmaceutical Co., Ltd.CompletedPolycystic Kidney, Autosomal DominantJapan
-
Otsuka Pharmaceutical Co., Ltd.CompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)Japan
-
University of North Carolina, Chapel HillOtsuka America PharmaceuticalCompletedHeart Diseases | Cardiovascular Diseases | Heart FailureUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka Pharmaceutical Co., Ltd.CompletedInappropriate ADH Syndrome | Water Intoxication | Hyponatremias | Water-Electrolyte ImbalancesUnited States